Pharma channel feed – Endpoints News

Pharma channel feed

Teva R&D chief out as new CEO picks up the ax and aims at deep cuts to rescue a faltering biopharma — report

8 years ago

Under pressure from copycats, Roche sues Pfizer over Herceptin rival

8 years ago

With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca

8 years ago

After unexpected tie, Amsterdam wins 'coin toss' for new EMA HQ

8 years ago

The top 10 hit parade of biopharma licensing deals for 2014-2017

8 years ago

Bayer AG taps PeptiDream in billion-dollar deal

8 years ago

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

8 years ago

A go-go FDA is opening up the fast lane to regenerative med approvals

8 years ago

Struggling Oncolytics Biotech signs $86.6M Asia deal with China's Adlai Nortye

8 years ago

Booming Regeneron gets the green light for a major expansion

8 years ago

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

8 years ago

The Pentagon's compromise: drug approvals to remain in FDA's hands

8 years ago

In blow to Shire, Roche bags an FDA OK for its blockbuster hemophilia A prospect

8 years ago

J&J goes back to Ionis for its second experimental pill for a GI autoimmune disease

8 years ago

You want to charge $1M for that gene therapy? Here’s where you’re wrong

8 years ago

Not your mom’s probiotic: GV-backed Evelo teams up with Mayo Clinic on microbiome drugs

8 years ago

Ultragenyx lands first FDA OK, with another on the horizon in shift to commercial ops

8 years ago

Alkermes touts equal efficacy of monthly Vivitrol against daily Suboxone

8 years ago

Genentech inks $650M deal with protein degradation pioneer Arvinas

8 years ago

AstraZeneca’s respiratory group scores FDA OK for a blockbuster severe asthma drug

8 years ago

Mirati bails on lead drug, shifts focus to I/O program

8 years ago

Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs

8 years ago

Pfizer CEO Read hands off drug development responsibilities to his hand picked successor

8 years ago

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

8 years ago

First page Previous page 312 313 314315316 317 318 Next page Last page